SEC Company Response from CAPRICOR THERAPEUTICS, INC. (CAPR) (CIK 0001133869) (CAPR) — Mar 15, 2011
CAPRICOR THERAPEUTICS, INC. (CAPR) (CIK 0001133869)
Date: March 15, 2011 · CIK: 0001133869 · Accession: 0001144204-11-014928
AI Filing Summary & Sentiment
Reasoning
Letter
VIA EDGAR Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Nile Therapeutics, Inc. (the “Company”)
Re:
Dear Sir/Madam:
As counsel for the Company and on its behalf, enclosed herewith is the Company’s Preliminary Proxy Statement on Schedule 14A relating to the Company’s 2011 Annual Meeting of Stockholders.
Please contact the undersigned at (612) 492-7369 if you have any questions or comments with respect to the Preliminary Proxy Statement.
Sincerely,
/s/ Christopher J. Melsha
Show Raw Text
CORRESP
1
filename1.htm
Unassociated Document
March 15, 2011
VIA EDGAR
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Re:
Nile Therapeutics, Inc. (the “Company”)
Dear Sir/Madam:
As counsel for the Company and on its behalf, enclosed herewith is the Company’s Preliminary Proxy Statement on Schedule 14A relating to the Company’s 2011 Annual Meeting of Stockholders.
Please contact the undersigned at (612) 492-7369 if you have any questions or comments with respect to the Preliminary Proxy Statement.
Sincerely,
/s/ Christopher J. Melsha
Christopher J. Melsha
Attorney
Direct Dial: 612.492.7369
Email: cmelsha@fredlaw.com
cc: Mr. Daron Evans
Chief Financial Officer
Nile Therapeutics, Inc.